DexCom (NASDAQ:DXCM) had its price target lifted by stock analysts at Jefferies Group from $58.00 to $70.00 in a research note issued to investors on Friday. The brokerage currently has a “buy” rating on the medical device company’s stock. Jefferies Group’s price objective would suggest a potential upside of 25.61% from the stock’s previous close.
A number of other research analysts also recently weighed in on DXCM. ValuEngine upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Barclays started coverage on shares of DexCom in a research report on Friday, September 15th. They issued an “equal weight” rating and a $76.00 price objective for the company. Robert W. Baird reiterated a “hold” rating and issued a $79.00 price objective on shares of DexCom in a research report on Sunday, September 10th. BMO Capital Markets reiterated a “buy” rating and issued a $90.00 price objective on shares of DexCom in a research report on Friday, September 8th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $87.00 price objective on shares of DexCom in a research report on Friday, September 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. DexCom has a consensus rating of “Buy” and an average price target of $70.19.
DexCom (NASDAQ:DXCM) traded down $0.98 during midday trading on Friday, reaching $55.73. 1,567,900 shares of the company were exchanged, compared to its average volume of 1,453,127. DexCom has a 52 week low of $42.62 and a 52 week high of $88.80. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50.
A number of hedge funds and other institutional investors have recently made changes to their positions in DXCM. Rathbone Brothers plc grew its stake in shares of DexCom by 5.3% in the 2nd quarter. Rathbone Brothers plc now owns 4,000 shares of the medical device company’s stock valued at $293,000 after buying an additional 200 shares during the period. Janney Montgomery Scott LLC grew its stake in shares of DexCom by 9.2% in the 2nd quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock valued at $216,000 after buying an additional 250 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of DexCom by 12.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock valued at $238,000 after buying an additional 354 shares during the period. Utah Retirement Systems grew its stake in shares of DexCom by 4.0% in the 2nd quarter. Utah Retirement Systems now owns 15,600 shares of the medical device company’s stock valued at $1,141,000 after buying an additional 600 shares during the period. Finally, Ithaka Group LLC grew its stake in shares of DexCom by 0.9% in the 2nd quarter. Ithaka Group LLC now owns 81,416 shares of the medical device company’s stock valued at $5,956,000 after buying an additional 703 shares during the period.
TRADEMARK VIOLATION NOTICE: “DexCom (DXCM) PT Raised to $70.00 at Jefferies Group” was originally posted by American Market News and is owned by of American Market News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/12/22/dexcom-dxcm-pt-raised-to-70-00-at-jefferies-group.html.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
